Weihai Disu

Weihai Disu Pharmaceutical is a specialized pharmaceutical manufacturing and R&D company based in Weihai, China, serving as a core subsidiary of Dizal Pharma. The company focuses on the production of active pharmaceutical ingredients (APIs) and advanced intermediates for innovative small molecule therapeutics. Its facilities are designed to meet international GMP standards, supporting the global clinical development and commercialization of oncology and immunology treatments. Weihai Disu plays a pivotal role in the supply chain for Dizal's lead products, including the EGFR inhibitor sunvozertinib and the JAK1 inhibitor golidocitinib. By integrating manufacturing capabilities with Dizal's research engine, the company ensures the scalable production of breakthrough medicines for unmet medical needs.